Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 13/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.43 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11326712 | 0.91 | ALK (0.51) | ALKJAK2EGFRIGF1RKCNH2 | |
| SCHEMBL11320105 | 0.83 | JAK2 (0.48) | ALKJAK2EGFRPTK2 | |
| SCHEMBL11303155 | 0.81 | ALK (0.53) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL11302133 | 0.80 | ALK (0.51) | ALKJAK2EGFRIGF1RKCNH2 | |
| SCHEMBL15795213 | 0.79 | ALK (0.55) | ALKEGFR | |
| SCHEMBL11298782 | 0.78 | ALK (0.52) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL15794995 | 0.78 | ALK (0.52) | ALKJAK2EGFR | |
| SCHEMBL11332820 | 0.78 | ALK (0.56) | ALKJAK2LRRK2 | |
| SCHEMBL11318522 | 0.77 | ZAP70 (0.45) | ALKJAK2 | |
| SCHEMBL11291476 | 0.76 | JAK2 (0.54) | ALKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | claimed |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2665725-A1 | BICYCLIC INHIBITORS OF ALK | AbbVie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012097683-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ACVR1, ACVR1B | ALK 1/4885JAK2 104/4885EGFR 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.